US pre-open: Futures trade lower ahead of FOMC meeting.Rolls-Royce appoints Jörg Stratmann as head of Power Systems.Berenberg raises target price on Craneware.Eve Sleep rocked by 'appalling' market conditions, shares plunge.FTSE 250 movers: Future CEO news sends shares plunging.Director dealings: Big Technologies exec makes £120k sale.US open: Stocks lower ahead of FOMC decision.Broker tips: Craneware, SSE, Good Energy.FTSE 100 movers: Haleon heads higher Ocado hit by downgrade.Moonpig backs FY guidance to focus on greeting card sales.London close: Stocks weaker as central bank jitters grow.Week ahead: BoE, Fed and BoJ in the spotlight.Wednesday preview: US Fed decision, UK public sector net borrowing data in focus.Europe close: Stocks slip as Riksbank delivers hawkish surprise.US close: Stocks weaker ahead of Fed's next move.
The value of investments can fall and you may get back less than you invested. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. All rights reserved and terms of use apply. News Source: © 2022 Web Financial Group (UK) Limited. "The company's earnings growth remains one of the highest in the sector and perhaps justifies a premium valuation, Mead and McGarry said.
The FTSE 100 drugs group's third quarter had various disappointments including revenue missing consensus by 1% and core earnings 6% less than expectations, the analysts said. "We expect more Covid-19 vaccine news flow on the horizon that suggests the shares are likely to be supported at current levels." "AstraZeneca has begun successful execution of its R&D pipeline," analysts Julie Mead and Steve McGarry said in a note to clients. They reduced their 2020 forecasts, predicting 8% revenue growth to $26.4bn, down from a previous estimate of $26.8bn, and core earnings up 16% to $4.08 per share compared with an earlier estimate of $4.18. HSBC'\\s analysts increased their rating on AstraZeneca shares to 'hold' from 'reduce' and nudge up their share price target to £72.60 from £71.20. The bank's analysts said they had harboured concerns about AstraZeneca's ability to turn research into revenue.Īfter Pfizer's announcement that its coronavirus vaccine, developed with BioNTech, was effective against Covid-19, HSBC said further positive news about vaccines should support the shares of AstraZeneca, which is working on a vaccine with Oxford University. Indirect Clients Supplementary Terms of BusinessĪstraZeneca's results showed good execution of its research pipeline with strong performances from cancer treatments Tagrisso, Imfinzi and Lynparza, HSBC said.Portfolios for Inheritance Tax (IHT) Mitigation.Alternative Investment Market (AIM) Portfolio.Junior Individual Savings Accounts (JISAs).Self-Invested Personal Pensions (SIPPs).
0 kommentar(er)
